analytical verification is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-07. Numbers and descriptions here follow the published literature rather than marketing material.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
== Structure == Although no crystallographic x-ray diffraction analyses have been published that depict the entire structure of ADAM10, one domain has been studied using this technique. The disintegrin and cysteine-rich domain (shown to the right) plays an essential role in regulation of protease activity in vivo. Recent experimental evidence suggests that this region, which is distinct from the active site, may be responsible for substrate specificity of the enzyme. It is proposed that this domain binds to particular regions of the enzyme's substrate, allowing peptide bond hydrolysis to occur in well defined locations on certain substrate proteins. The proposed active site of ADAM10 has been identified by sequence analysis, and is identical to enzymes in the Snake Venom metalloprotein domain family. The consensus sequence for catalytically active ADAM proteins is HEXGHNLGXXHD. Structural analysis of ADAM17, which has the same active site sequence as ADAM10, suggests that the three histidines in this sequence bind a Zn2+ atom, and that the glutamate is the catalytic residue.
Cost: Flame ionization detectors are relatively inexpensive to acquire and operate. Low maintenance requirements: Apart from cleaning or replacing the FID jet, these detectors require little maintenance. Rugged construction: FIDs are relatively resistant to misuse. Linearity and detection ranges: FIDs can measure organic substance concentration at very low (10−13 g/s) and very high levels, having a linear response range of 107 g/s.
== Tritium breeding == Fusion reactions, such as those in the proposed ITER thermonuclear demonstrator reactor, are fueled by tritium and deuterium. Tritium resources are extremely limited in their availability, with total resources currently estimated at twenty kilograms. Lithium-containing ceramic pebbles can be used as solid breeder materials in a component known as a helium-cooled breeder blanket for the production of tritium. The breeding blanket constitutes a key component of the ITER reactor design. In such reactor designs tritium is produced by neutrons leaving the plasma and interacting with lithium in the blanket. Li2TiO3 along with Li4SiO4 are attractive as tritium breeding materials because they exhibit high tritium release, low activation, and chemical stability.
== Physiology and pathophysiology == Beta cells play a paramount role in glucose homeostasis. Progressive loss of insulin secretory capacity is a key defect associated with the transition from a healthy glycaemic state to hyperglycaemia, characteristic of untreated diabetes mellitus. In type 1 diabetes mellitus and pancreatogenic diabetes beta cell destruction is a primary event from the perspective of the feedback loop. In type 2 diabetes beta cell dysfunction is an essential constituent as well, but subsequent to the development of insulin resistance. Other mechanisms, including lipotoxicity, amyloid deposition, oxidative stress, mitochondrial dysfunction, ER stress and inflammation may be involved as well. The beta cell loss in type 2 diabetes is mainly caused by reduced beta cell number rather than size. Hyperglycaemia becomes clinically significant once insulin over-secretion can no longer compensate for the degree of insulin resistance. It remains an unsolved question if impaired pancreatic beta cell function or hypersecretion of insulin represent the primary event in the pathogenesis of type 2 diabetes. Both scenarios may be cause and consequence, and it has been postulated that the direction of causality depends on the respective subtype of diabetes. Therefore, they may be part of a complex feedback loop involving glucose toxicity leading to a biphasic response, thereby preventing neoplastic effects of dynamical compensation by mutant takeover.
1% w/v BCA-Na2 (CAS: 979-88-4) 2% w/v Na2CO3·H2O (CAS: 5968-11-6) 0.16% w/v Na2 tartrate (CAS: 868-18-8) 0.4% w/v NaOH (CAS: 1310-73-2) 0.95% w/v NaHCO3 (CAS: 144-55-8) Add 50% NaOH or solid NaHCO3 to adjust the pH to 11.25 A suggested but untested alternative formulation in the Smith manuscript is to leave out the NaOH (and presumably not perform the manual pH adjustment to 11.25), but instead to dissolve the other components in a preprepared buffer of 0.25 M Na2CO3 and 0.01 M NaHCO3. Notably, Smith synthesized their own BCA via the Pfitzinger reaction of isatin and acetoin, substituting NaOH for KOH but otherwise following the synthetic method of Lesene and Henze, as the BCA available from commercial vendors of that time was too impure for their use. At least three successive recrystallizations of their synthesized BCA from 70˚C water was needed to sufficiently purify it for the assay. Reagent B
Sources: en.wikipedia.org
=== Indirect immunofluorescence === Indirect immunofluorescence is one of the most commonly used tests for ANAs. Typically, HEp-2 cells are used as a substrate to detect the antibodies in human serum. Microscope slides are coated with HEp-2 cells and the serum is incubated with the cells. If the said and targeted antibodies are present then they will bind to the antigens on the cells; in the case of ANAs, the antibodies will bind to the nucleus. These can be visualised by adding a fluorescent tagged (usually FITC or rhodopsin B) anti-human antibody that binds to the antibodies. The molecule will fluoresce when a specific wavelength of light shines on it, which can be seen under the microscope. Depending on the antibody present in the human serum and the localisation of the antigen in the cell, distinct patterns of fluorescence will be seen on the HEp-2 cells. Levels of antibodies are analysed by performing dilutions on blood serum. An ANA test is considered positive if fluorescence is seen at a titre of 1:40/1:80. Higher titres are more clinically significant as low positives (≤1:160) are found in up to 20% of healthy individuals, especially the elderly. Only around 5% of the healthy population have ANA titres of 1:160 or higher.
The Humr are one of the tribes in the Baggara ethnic group, native to southwestern Kordofan in Sudan who speak Shuwa (Chadian Arabic), make a non-alcoholic drink from the liver and bone marrow of the giraffe, which they call umm nyolokh. They claim it is intoxicating (Arabic سكران sakran), causing dreams and even waking hallucinations. Anthropologist Ian Cunnison accompanied the Humr on one of their giraffe-hunting expeditions in the late 1950s, and noted that:
On 9 May 2024, control Judge Juan Manuel Fernández López rejected Agüero's appeals against the prosecution's petition to take her to trial, and ordered that she stand trial on five counts of aggravated murder, as well as eight other counts of attempted murder. Along with Agüero, Judge Fernández López also ordered that 10 officials face trial at the same courtroom where Agüero will be tried. The trial against Brenda Agüero and the other ten defendants commenced on 6 January 2025. Agüero denied committing the crimes during her first testimony, saying that there is "no possibility that harming another person crosses my mind; much less a child." On 22 January, the mother of one of the babies who decompensated (a baby girl named Isabella) testified that she saw Agüero injecting her baby while the little girl was in the cradle. The woman said that the baby cried as Agüero injected her shortly before decompensating. On 30 January, medical professionals testified at the trial, saying that the babies did not die from a natural cause, and confirmed that the levels of potassium or insulin in their bodies were injected deliberately. On 4 February, a neonatal doctor testified that during her shift on 6 June 2022, when two healthy babies died without presumptive cause, she saw Brenda Agüero with a baby in her arms, and that Agüero told her that the baby "was not well". The baby later died from a serious case of bradycardia. The doctor also confirmed that the nature of the deaths of these healthy babies raised suspicions from the doctors who attempted to resuscitate them.
=== Religious alignment === Since 1660, nonconformist Protestants have played a major role in English politics. Relatively few MPs were Dissenters. However the Dissenters were a major voting bloc in many areas, such as the East Midlands. They were very well organised and highly motivated and largely won over the Whigs and Liberals to their cause. Down to the 1830s, Dissenters demanded removal of political and civil disabilities that applied to them (especially those in the Test and Corporation Acts). The Anglican establishment strongly resisted until 1828. Numerous reforms of voting rights, especially that of 1832, increased the political power of Dissenters. They demanded an end to compulsory church rates, in which local taxes went only to Anglican churches. They finally achieved the end of religious tests for university degrees in 1905. Gladstone brought the majority of Dissenters around to support for Home Rule for Ireland, putting the dissenting Protestants in league with the Irish Roman Catholics in an otherwise unlikely alliance. The Dissenters gave significant support to moralistic issues, such as temperance and sabbath enforcement. The nonconformist conscience, as it was called, was repeatedly called upon by Gladstone for support for his moralistic foreign policy. In election after election, Protestant ministers rallied their congregations to the Liberal ticket. In Scotland, the Presbyterians played a similar role to the Nonconformist Methodists, Baptists and other groups in England and Wales.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.